KR20140055154A - Amygdalin improving skin aging or inflammation with protecting skin from external harmful materials such as ultraviolet ray etc - Google Patents

Abstract

The present invention discloses a composition for improving aging or inflammation of the skin, characterized by containing as an active ingredient Amygdalin to protect the skin from skin damage which is induced by adverse external environment such as ultraviolet rays. The composition constitutes a toner, an essence, a moisturizer, a cream, a gel, an ointment, a patch, a foundation, a makeup base, a sunscreen, a bath salt, a soap, a liquid cleanser, or a spray.

Description

[0002] Amygdalin is a substance that protects skin from harmful substances such as ultraviolet rays and improves skin inflammation or aging.

The present invention relates to a composition for ameliorating skin aging or improving inflammation, which comprises Amygdalin as an active ingredient which protects skin from harmful substances such as ultraviolet rays and improves skin aging.

As human skin grows older, it undergoes many changes due to intradermal factors and extrinsic factors. The inner skin of the skin cells is degraded and the biosynthesis of the skin constituting proteins is reduced. In addition, due to the harmful factors such as ultraviolet ray, yellow dust, organic solvent, heat, etc., dryness, wrinkles, elasticity decrease, skin sagging, And black blotch, and the like. Among external harmful substances, ultraviolet rays have been recognized as a major cause of aging as well as aging skin through various action mechanisms, and many studies have been conducted. Skin aging by ultraviolet rays has been shown to induce skin aging through various action pathways such as inflammatory cytokine production, noxious oxygen species production, gene damage, and cell necrosis. Until recently, various studies It is progressing.

However, studies on the mechanisms of skin aging caused by ultraviolet rays are being actively carried out, but studies on substances that prevent and improve skin aging from these causes have not been conducted yet. In particular, currently used ingredients in cosmetics are simply ingredients that physically and temporarily block and absorb ultraviolet rays, and there is no substance that prevents skin aging by inhibiting ultraviolet-induced mechanisms of skin aging .

        Accordingly, the present inventors have confirmed that Amygdalin is a substance having a phenomenon that fundamentally prevents and / or ameliorates skin aging from an action mechanism that causes skin aging by ultraviolet rays, and at the same time has an excellent skin aging improving physiological activity, .

The inventors of the present invention found that amygdalin is effective in improving skin aging or improving inflammation and improving the skin aging effect in a variety of materials. And the present invention has been completed.

Accordingly, an object of the present invention is to provide a cosmetic composition for improving skin aging or for improving inflammation.

The present invention relates to a cosmetic composition which is excellent in safety and has an excellent skin aging-improving effect, and is characterized by containing amygdalin as an active ingredient having an effect of improving skin aging or improving inflammation.

Hereinafter, the present invention will be described more specifically.

So far, researches on skin aging phenomenon and cause by ultraviolet rays have been conducted, and ultraviolet rays have been known to promote skin aging through various mechanisms. Based on these studies, cosmetics have been developed to temporarily and physically block ultraviolet rays. However, development of a substance that suppresses and improves the underlying causes of skin aging by inhibiting various skin aging mechanisms that cause skin aging by ultraviolet rays Was not progressing. Accordingly, the inventors of the present invention have conducted studies to develop a material that protects skin and inhibits skin aging caused by inflammatory cytokines, and at the same time, develops a skin aging-resistant material. As a result, Amygdalin It has been found that this ultraviolet ray protects skin cells and has an excellent inhibitory effect on inflammatory cytokines that induces senescence, has no toxicity, has good stability, and exhibits an excellent aging-improving effect, thereby completing the present invention.

It is everyone's desire to prevent skin aging and to have young, beautiful skin. Skin aging can be categorized as natural aging caused by photoaging caused by external harmful environment such as ultraviolet rays and time. These two aging phenomena commonly cause wrinkles on the skin, or cause various aging phenomena such as stain and pigmentation, thereby damaging the appearance of the skin and making it look older.

In particular, ultraviolet rays are the most important cause of skin aging, and many people have studied skin aging phenomena and causes caused by ultraviolet rays. In order to maintain skin beauty, various raw materials have been developed. However, It has been a temporary and physical ingredient that absorbs and has not been developed to fundamentally block the mechanism of skin aging caused by ultraviolet light.

Accordingly, the present inventors have conducted research to develop a novel skin aging-improving material that improves skin aging by inhibiting inflammatory cytokines that are the cause of skin aging, safely and safely without skin irritation, protecting skin cells by ultraviolet rays As a result, the present inventors have found that amygdalin has a strong aging-improving effect or an inflammation-improving effect.

Amygdalin provided by the present invention is excellent in protection of skin cells by ultraviolet rays, excellent in skin aging-improving effect or inflammation-improving effect by inhibiting inflammatory cytokine production, and also excellent in safety of raw material itself.

The skin-aging-improving cosmetic composition according to the present invention is not particularly limited in its formulation and may be formulated into, for example, a lotion, essence, cream, pack, gel, lotion, ointment, patch or spray.

The Amygdalin content in the formulation may be 0.000001 to 20% by weight, preferably 0.00001 to 10% by weight, based on the total weight of the composition.

The composition of the present invention can be identified as a cosmetic composition in a specific embodiment.

When the composition of the present invention is recognized as a cosmetic composition, the cosmetic composition may be prepared in various forms, for example, emulsion, lotion, cream (oil-in-water type, oil water type, multiphase), solution, suspension (Water and water), anhydrous products (oil and glycol), gel, mask, pack, powder and the like.

The cosmetic composition of the present invention may contain an acceptable carrier in cosmetic preparations in addition to Amygdalin.

As used herein, the term " acceptable carrier for cosmetic preparation "refers to a compound or composition which is already known and used in the cosmetic preparations, or which is a compound or composition to be developed in the future, and which has no toxicity, instability or irritability It says.

The carrier may be included in the cosmetic composition of the present invention in an amount of about 1% by weight to about 99.99% by weight, preferably about 90% by weight to about 99.99% by weight of the composition, based on the total weight thereof.

However, since the ratio depends on the formulation as described above in which the cosmetic composition of the present invention is prepared and on its specific application site (face, neck, etc.) or its desirable application amount, the ratio is, in any aspect, And should not be construed as limiting the scope of the invention.

Examples of the carrier include alcohols, oils, surfactants, fatty acids, silicone oils, humectants, moisturizers, viscosifiers, emulsifiers, stabilizers, sunscreens, coloring agents and perfumes.

The compounds / compositions which can be used as the above-mentioned alcohol, oil, surfactant, fatty acid, silicone oil, humectant, humectant, viscous modifier, emulsion, stabilizer, ultraviolet screening agent, coloring agent and fragrance are already known in the art The appropriate substance / composition can be selected and used.

On the other hand, the composition of the present invention can be identified as a pharmaceutical composition in another specific embodiment.

When the composition of the present invention is identified as a pharmaceutical composition, its pharmacological effect can be grasped as skin inflammation or whitening improving effect.

The pharmaceutical composition of the present invention may contain a pharmaceutically acceptable carrier in addition to Amygdalin as an active ingredient. Such pharmaceutically acceptable carriers are those conventionally used in pharmaceutical preparations, and include lactose, dextrose, sucrose, But are not limited to, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, Tartrate, magnesium stearate, mineral oil, and the like, but is not limited thereto.

The pharmaceutical composition of the present invention may further comprise, as an additive, a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative and the like.

The carrier may be included in the pharmaceutical composition of the present invention in an amount of about 1% by weight to about 99.99% by weight, preferably about 90% by weight to about 99.99% by weight, based on the total weight of the pharmaceutical composition, To about 20% by weight.

On the other hand, the pharmaceutical composition of the present invention can be administered orally or parenterally, and most preferably, it can be directly administered to the skin by local administration.

The pharmaceutical composition of the present invention can be prepared in unit dose form by formulating it with a pharmaceutically acceptable carrier and / or excipient or can be manufactured by inserting it into a multi-dose container. The formulations may be in the form of a solution, suspension or emulsion, or may contain an agent such as an agent, an excipient, a powder, a granule, a tablet, a warning agent, a lotion,

The daily dose of the pharmaceutical composition of the present invention is usually 0.001 to 150 mg / kg body weight, and may be administered once or several times. However, since the dosage of the pharmaceutical composition of the present invention is determined in view of various related factors such as route of administration, age, sex, weight, and patient's severity of the patient, the dose is limited in any aspect to the scope of the present invention Should not be understood to be.

The composition of the present invention can be identified as a soap composition in another specific embodiment.

When the composition of the present invention is recognized as a soap composition, the soap composition of the present invention can be prepared by incorporating Amygdalin into a soap base, and can be prepared as an additive including a skin moisturizer, an emulsifier, a water softener and the like.

Examples of the soap base material include vegetable oils such as palm oil, palm oil, soybean oil, perm free oil, olive oil and palm kernel oil or animal fats such as tallow, lard, sunshine and fish oil. Examples of the skin moisturizers include glycerin, erythritol, polyethylene glycol , Propylene glycol, butylene glycol, pentylene glycol, hexyl glycol, isopropyl myristate, silicone derivatives, aloe vera, sorbitol and the like. Examples of the emulsifier include natural oils, wax fatty alcohols, hydrocarbons, May be used. As the water softening agent, tetrasodium ethylenediate and the like may be used.

The soap composition of the present invention may further contain, as an additive, an antibacterial agent, a dispersant, a foam inhibitor, a solvent, a scouring inhibitor, a corrosion inhibitor, a fragrance, a dye, a sequestering agent, an antioxidant and an antiseptic.

In the soap composition of the present invention, the soap base or additive may be included in a content commonly used in the art, wherein the soap base generally comprises from 99.999% to 50% by weight, based on the total weight of the soap composition And the additive may be added in an amount of 1 wt% to 20 wt%.

As described above, according to the present invention, Amygdalin, which can be usefully used for improving skin aging and the like, can be provided as a cosmetic composition.

Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these examples and experimental examples.

≪ Examples 1 and 2 Preparation of cosmetic composition containing Amygdalin >

A cosmetic composition was prepared to test the skin aging improvement effect on the human body. The raw materials 1 to 7 of the raw materials shown in Table 1 below were mixed and dissolved at 70 캜 into a water part, and raw materials 8 to 14 were dissolved at 70 캜 to obtain an oil part. The oil part was added to the water part and agitated with a homomixer (Tokushu Kika, Japan) for primary emulsification. After the air bubbles were removed, the mixture was cooled to room temperature to prepare a cosmetic composition of a nutritional lotion formulation.

ingredient Example 1 Example 2 Comparative Example 1 1. Purified water To 100 To 100 To 100 2. Glycerin 8.0 8.0 8.0 3. Butylene glycol 4.0 4.0 4.0 4. Hyaluronic acid extract 5.0 5.0 5.0 5. Beta Glucan 7.0 7.0 7.0 6. Carbomer 0.1 0.1 0.1 7. Amygdaline 0.001 0.002 - 8. Caprylic Capric Triglyceride 8.0 8.0 8.0 9. Squalane 5.0 5.0 5.0 10. Cetearyl glucoside 1.5 1.5 1.5 11. Sorbitan stearate 0.4 0.4 0.4 12. Cetearyl alcohol 1.0 1.0 1.0 13. Preservatives Suitable amount Suitable amount Suitable amount 14. Incense Suitable amount Suitable amount Suitable amount 15. Triethanolamine 0.1 0.1 0.1

<Experimental Example 1 Skin Protection Test>

The degree of skin proliferation which tests the protective effect of skin cells by ultraviolet rays of the present invention was measured by incubation of HaCaT cells which are keratinocytes present in skin epidermis. HaCaT cells were inoculated into 96-well microplates at a concentration of 1 × 10 ⁴ cells / well and cultured in a CO ₂ incubator at 37 ° C. and 5% concentration for 24 hours. After the medium was removed, the cells were washed with PBS (Phosphate Buffered Saline) and cultured in DMEM (Gibco) medium containing no concentration of Amygdalin for 24 hours. On the next day, the medium was removed, 100 μL of PBS was added, and ultraviolet light was irradiated. Then DMEM medium containing no serum was added and cultured in a CO ₂ incubator at 37 ° C and 5% concentration. As a control group 1, a DMEM without serum was added, and ultraviolet light was irradiated. Control group 2 was not irradiated with ultraviolet light.

Ultraviolet irradiation was carried out using VILBER LOURMAT so that ultraviolet ray B was 30 mJ / cm ² , at which the cell starts to die.

Cell viability was performed using CCK-8 (Cell Counting Kit-8, DOJINDO Laboratories) as follows. The cells were incubated at 37 ° C in a 5% CO ₂ incubator for 1 hour and 30 minutes, and the absorbance was measured at 450 nm using an ELISA reader (SPECTRA MAX 190, Molecular Devices) . At this time, to determine the cell survival effect of amygdalin, three times each was carried out to obtain an average value. Cell viability was evaluated by the ratio of absorbance to control 2.

Table 2 shows the cell survival results of the above substances.

Test substance Cell survival rate (%) Control 1 82.3 Control group 2 100 10 ppm Amygdaline 120.0 20 ppm Amygdaline 114.3

<Experimental Example 2: Inhibitory effect on inflammatory cytokine production using HaCaT cells>

Amygdalin was treated with HaCaT cells to inhibit inflammatory cytokine production. HaCaT cells were inoculated into 96-well microplates at a concentration of 1 × 10 ⁴ cells / well and cultured in a CO ₂ incubator at 37 ° C. and 5% concentration for 24 hours. After the medium was removed, the cells were washed with PBS (Phosphate Buffered Saline) and cultured in DMEM (Gibco) medium containing no concentration of Amygdalin for 24 hours. On the next day, the medium was removed, 100 μL of PBS was added, and ultraviolet light was irradiated. Then DMEM medium containing no serum was added and cultured in a CO ₂ incubator at 37 ° C and 5% concentration. DMEM without serum was added as a control, and ultraviolet light was irradiated. Ultraviolet irradiation was performed using VILBER LOURMAT so that ultraviolet B was 20 mJ / cm ^2, which does not kill cells.

Media were collected on a time-of-day basis to analyze inflammatory cytokines. The inflammatory cytokines were quantified using Quantikine ELISA Human IL-1a and IL-23 (R & D Systems), respectively, with interleukin 1 alpha (IL-1a) and interleukin 23 (IL-23; Interleukin-23). Inflammatory cytokine inhibition rates are shown in Tables 3 and 4 below in terms of% inhibition of inflammatory cytokines by time.

Test substance After 1 hour of ultraviolet irradiation After 6 hours of ultraviolet irradiation After 24 hours of ultraviolet irradiation After 48 hours of ultraviolet irradiation 10 ppm Amygdaline 36.9 41.2 - - 20 ppm Amygdaline 47.8 72.6 - -

Test substance After 1 hour of ultraviolet irradiation After 6 hours of ultraviolet irradiation After 24 hours of ultraviolet irradiation After 48 hours of ultraviolet irradiation 10 ppm Amygdaline 27.3 35.0 26.1 - 20 ppm Amygdaline 57.8 67.1 50.5 -

From Table 3 and 4, it can be seen that amygdalin has excellent inhibitory effect on inflammatory cytokine, which is the cause of aging caused by ultraviolet rays.

&Lt; Experimental Example 3: Whitening and inflammation inhibitory effect on human skin >

Twenty-five healthy persons were adhered with opaque tapes each having four holes each having a diameter of 1.5 cm on the upper forearm of the subject, and after applying the cosmetic composition of Examples 1 and 2 and Comparative Example 1, (UVB) of 1.5 times to 2 times of the minimum erythema dose (Minimal Erythema Dose). The degree of skin erythema and degree of darkening induced by ultraviolet rays was measured using a color difference meter.

The determination of the effect was made by measuring the "L" value of the skin tone and the "a" value of the skin tone in Chromameter CR300 (Minolta, Japan).

When the test substance is applied and the effect of whitening is effective, the L value before the start of the test and the L value (ΔL), which is the difference of the L value after the black formation is completely formed, Value and ultraviolet rays. The smaller the value of delta a (Δa), which is the difference of a value after inflammation, is effective. The changes in ΔL value and Δa value are shown in Table 5 and 6 below. The comparison site was defined as a site where the sample was not applied.

Test substance Whitening effect (? L) Control group 8.23 Example 1 1.17 Example 2 1.14 Comparative Example 1 1.34

Test substance Inflammation inhibitory effect (? A) Control group 7.66 Example 1 1.38 Example 2 1.26 Comparative Example 1 1.97

As can be seen from the above Tables 5 and 6, the compositions of Examples 1 and 2 containing Amygdalin have the effect of preventing pigmentation due to melanin, which is one of the aging phenomena caused by ultraviolet rays, Lt; RTI ID = 0.0 &gt; inflammatory &lt; / RTI &gt;

<Experimental Example 4 Verification of Safety through Amygdalin Human Cumulative Patch Test>

The skin lotion compositions of Examples 1 and 2 and the cosmetic compositions of Comparative Example 1 were subjected to cumulative skin stimulation tests to verify skin safety. A total of 9 24 hour cumulative epidermal patches are performed on the upper forearm for 20 healthy adults. The application method is Finn chamber or a similar type of chamber. After applying 15 조성물 of composition per chamber, apply the patch and measure the degree of reaction on the skin every time. The results are shown in Table 7 below. At this time, a score of ± (one point), + (two points) and ++ (four points) (highest score) is given, and a safe composition is determined when the average degree of reaction is less than 3.

Average Reactivity = (Number of Reactors X Reactivity / Total Number of Subjects X Highest Score X 100) ÷ Total Number of Tests

Test substance Number of subjects who responded Average
Reactivity 1 week 2 weeks 3 weeks Primary Secondary Third Fourth 5th 6th Seventh 8th car 9th ± + ++ ± + ++ ± + ++ ± + ++ ± + ++ ± + ++ ± + ++ ± + ++ ± + ++ Example 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - 0.00 Example 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - 0.00 Comparative Example 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - 0.00 Subject 20 20 20 20 20 20 20 20 20

From the results of Table 7, it can be seen that all the compositions of the Examples did not exhibit the cumulative stimulation pattern as with all the compositions of the Comparative Examples.

From the above experiments, Amygdalin protects the skin from ultraviolet rays to suppress and improve skin aging. In addition, it inhibits inflammation induced by ultraviolet rays by inhibiting the expression of inflammatory cytokines, which is the fundamental cause of skin aging caused by ultraviolet rays. It can be used as formulations such as lotion, essence, lotion, cream, pack, gel, ointment, patch, spray or the like which is excellent in the effect of improving skin aging by fundamentally preventing and improving the skin, have.

Claims (5)

A cosmetic composition for improving skin aging characterized by containing amygdalin as an active ingredient A cosmetic composition for improving skin inflammation caused by ultraviolet rays or the like, which comprises amygdalin as an active ingredient 3. The composition according to claim 1 or 2, wherein the composition contains 0.000001 to 30% by weight of Amygdalin as an active ingredient. The composition according to claim 1, wherein the composition is selected from the group consisting of lotion, essence, lotion, cream, pack, gel, ointment, patch, foundation, makeup base, ultraviolet screening agent, bathing agent, soap, liquid cleansing agent, &Lt; / RTI &gt; wherein the composition has a formulation. The composition of claim 1, wherein the composition has an oral or parenteral formulation.